Springhill Fund Asset Management (HK) Co Ltd
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 13, 2025), Springhill Fund Asset Management (HK) Co Ltd reported 17 stock positions worth $61.6 million. Its top holding was Verona Pharma (VRNA) at 10.2% of the portfolio, followed by Legend Biotech Corp.-ADR (LEGN, 10.1%) and Cytokinetics (CYTK, 10.0%).
- Most Recent 13F
- Q3 2025
- Location
- HONG KONG, K3
- CIK
- 0001911270
- Portfolio Value
- $61.6M (Q4 2024)
- SEC Filing
- 0001846639-25-000002 ↗ filed Feb 13, 2025
Holdings Value
Holdings 17 stocks · $61.6M
| VRNA Verona Pharma Ltd. | 10.22% | 135,452 | $6.3M | — |
| LEGN Legend Biotech Corp.-ADR | 10.08% | 190,800 | $6.2M | — |
| CYTK Cytokinetics Inc. | 9.99% | 130,735 | $6.1M | — |
| AZN Astrazeneca PLC-Spons ADR | 8.14% | 76,500 | $5.0M | — |
| INSM Insmed Inc. | 7.79% | 69,500 | $4.8M | — |
| VERA Vera Therapeutics Inc. | 7.51% | 109,400 | $4.6M | — |
| COGT Cogent Biosciences Inc. | 6.95% | 548,554 | $4.3M | — |
| AKRO Akero Therapeutics Inc. | 6.83% | 151,200 | $4.2M | — |
| MRUS Merus NV | 5.72% | 83,800 | $3.5M | — |
| CGEM Cullinan Therapeutics Inc. | 5.47% | 276,400 | $3.4M | — |
| DYN Dyne Therapeutics Inc. | 5.02% | 131,200 | $3.1M | — |
| NRIX Nurix Therapeutics Inc. | 4.91% | 160,500 | $3.0M | — |
| DRUG Bright Minds Biosciences Inc. | 3.55% | 60,648 | $2.2M | — |
| BCYC Bicycle Therapeutics PLC-ADR | 2.65% | 116,400 | $1.6M | — |
| JANX Janux Therapeutics Inc. | 2.57% | 29,600 | $1.6M | — |
| ABVX Abivax SA-ADR | 2.47% | 207,600 | $1.5M | — |
| SLNO Soleno Therapeutics Inc. | 0.13% | 1,793 | $81K | — |
Portfolio Sells Q4 2024
No earlier filing to compare with.
Portfolio Buys Q4 2024
No earlier filing to compare with.